333 results on '"Fornier, Monica"'
Search Results
52. Epothilones in breast cancer: current status and future directions
53. Anabolic Therapies for Osteoporosis
54. Serum HER-1/neu and relative resistance to trastuzumab-based therapy in patients with metastatic breast cancer
55. A Prospective, Longitudinal Study of the Functional Status and Quality of Life of Older Patients with Breast Cancer Receiving Adjuvant Chemotherapy
56. Cognitive Function of Older Patients Receiving Adjuvant Chemotherapy for Breast Cancer: A Pilot Prospective Longitudinal Study
57. Incidence of chemotherapy-induced, long-term amenorrhea in patients with breast carcinoma age 40 years and younger after adjuvant anthracycline and taxane
58. Serum HER2 extracellular domain (ECD) correlates with HER2 status by immunohistochemistry (IHC) and fluorescent in-situ hybridization (FISH), and with response rate (RR) in metastatic breast cancer (MBC) patients (pts) treated with weekly (W) trastuzumab (H) and paclitaxel (T)
59. Incidence of taxane-induced amenorrhea in breast cancer patients ≤ 40 years of age
60. Weekly Trastuzumab and Paclitaxel Therapy for Metastatic Breast Cancer With Analysis of Efficacy by HER2 Immunophenotype and Gene Amplification
61. Efficacy and Safety of Gemcitabine With Trastuzumab and Pertuzumab After Prior Pertuzumab-Based Therapy Among Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
62. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
63. Endocrine Therapy–Induced Alopecia in Patients With Breast Cancer
64. Erratum to: A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma
65. Depressive symptoms and schizophrenic relapses: The effect of four neuroleptic drugs
66. Less Intense Dosing Schedule for a Bone-Modifying Agent
67. Phase II study of gemcitabine (G), trastuzumab (H), and pertuzumab (P) for HER2-positive metastatic breast cancer (MBC) after prior pertuzumab-based therapy.
68. HER2-positive breast cancer: beyond trastuzumab
69. Evolving role of the epothilones
70. LORELEI: A Phase II randomized, double-blind study of neoadjuvant letrozole plus taselisib (GDC-0032) versus letrozole plus placebo in postmenopausal women with ER-positive/HER2-negative, early-stage breast cancer.
71. Denosumab and fracture risk in women with breast cancer
72. Eribulin mesylate in patients with locally advanced unresectable or metastatic breast cancer: results and implications of the clinical trials
73. A combined screening approach of Fracture (Fx) Risk Algorithm (FRAX) and Trabecular Bone Score (TBS) to identify osteoporotic-range fracture risk (ORFR) in breast cancer (BC) patients treated with adjuvant aromatase inhibitor (AI).
74. Phase I study of LJM716, BYL719, and trastuzumab in patients (pts) with HER2-amplified (HER2+) metastatic breast cancer (MBC).
75. Efficacy of paxman scalp cooling system at lower temperatures for prevention of anthracycline associated chemotherapy induced alopecia.
76. Phase II Study of Paclitaxel Given Once per Week Along With Trastuzumab and Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metastatic Breast Cancer
77. Serum metabolomic profiles evaluated after surgery may identify patients with oestrogen receptor negative early breast cancer at increased risk of disease recurrence. Results from a retrospective study
78. Phase II feasibility study of paclitaxel (T) with trastuzumab (H) and lapatinib (L) for node-negative, HER2-positive breast cancer (BC).
79. NCCN Task Force Report: Bone Health in Cancer Care
80. Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC).
81. Increased Levels of Urinary PGE-M, a Biomarker of Inflammation, Occur in Association with Obesity, Aging, and Lung Metastases in Patients with Breast Cancer
82. Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with HER2-overexpressing metastatic breast cancer (MBC).
83. A translational study to investigate the association between smoking-induced lung inflammation and lung metastases (LM) from breast cancer (BC).
84. Chemotherapy in patients with heavily pretreated metastatic breast cancer: overview
85. Approved chemotherapy agents for patients with metastatic breast cancer previously exposed to taxanes and anthracyclines
86. Choosing chemotherapy for patients with metastatic breast cancer previously exposed to taxanes and anthracyclines: other agents
87. The Paradox of Triple Negative Breast Cancer: Novel Approaches to Treatment
88. Reply to M.S. Aapro
89. A Feasibility Study of Bevacizumab plus Dose-Dense Doxorubicin–Cyclophosphamide (AC) Followed by Nanoparticle Albumin–Bound Paclitaxel in Early-Stage Breast Cancer
90. Denosumab: Second Chapter in Controlling Bone Metastases or a New Book?
91. Locoregional Outcomes of Inflammatory Breast Cancer Patients Treated With Standard Fractionation Radiation and Daily Skin Bolus in the Taxane Era
92. Feasibility Trial of Letrozole in Combination With Bevacizumab in Patients With Metastatic Breast Cancer
93. Erratum to: A pilot study of dose-dense adjuvant paclitaxel without growth factor support for women with early breast carcinoma
94. NCCN Task Force Report: Bone Health in Cancer Care
95. Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-phase II study aimed at cardiotoxicity
96. Microtubule Active Agents: Beyond the Taxane Frontier
97. Osteonecrosis of the Jaw Related to Bevacizumab
98. Osteonecrosis of the Maxilla and Mandible in Patients with Advanced Cancer Treated with Bisphosphonate Therapy
99. The Safety of Dose-Dense Doxorubicin and Cyclophosphamide Followed by Paclitaxel With Trastuzumab in HER-2/neu Overexpressed/Amplified Breast Cancer
100. Ixabepilone
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.